Is erlotinib for first-line use in EGFR+ non-small-cell lung cancer cost-effective?
David L Veenstra
Consultant or Advisory Role - Genentech
Preeti S. Bajaj
Consultant or Advisory Role - Genentech
Josh John Carlson
Consultant or Advisory Role - Genentech
Hans-Peter Goertz
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Roche